BioSpace News Archive

Synlogic, Inc. announced the termination of its collaboration with AbbVie, a global, research-based biopharmaceutical company, for the development of Synthetic Biotic medicines for the potential treatment of inflammatory bowel disease.

Statistically Significant One Month Increases in P1NP Biomarker from First 50% of Patients with Highest Dose of EB613

Medtronic plc announced financial results for its fourth quarter and fiscal year 2020, which ended April 24, 2020.

As the COVID-19 pandemic stabilizes and hospitals begin to plan for surgeries that have been postponed, surgeons and decision makers will face ongoing challenges in prioritizing care until our health-care system is fully re-opened.

ASIA announced that it had entered an agreement with Swysh Inc., an Alberta company focused on the conduct of specific cannabinoid-based research and development activities and that owns proprietary technology and related intellectual property aimed at providing the basis for creation of topical and systemic treatments for a variety of external and internal conditions and ailments, including a number of anti-viral and preventative health-care applications.

NanoViricides, Inc. a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced that strong effectiveness against infection by an ACE2-utilizing coronavirus in an animal model has been observed for the drug candidates it is developing against SARS-CoV-2 to treat COVID-19 spectrum of diseases.

Xenetic Biosciences, Inc. announced it has entered into a research funding and option agreement with Scripps Research to advance the development of the XCART™ technology for B cell malignancies.

Tarus Therapeutics Inc., an innovative biotechnology company developing adenosine receptor antagonists for cancer immunotherapy and select non-oncology indications, announced the appointments of David R. Epstein and C. David Nicholson, PhD, to its Board of Directors, effective May 14, 2020.

TransEnterix, Inc., a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, announced that the Sinai Health System in Chicago has entered into an agreement to lease and utilize a Senhance® Surgical System, which would be the first facility in Chicago to move in this direction.

ADMA Biologics, Inc., announced it has commenced the collection of convalescent plasma through its wholly-owned subsidiary, ADMA BioCenters Georgia Inc., from individuals who have recovered from COVID-19.